Ark Therapeutics Ltd Withdraws Its Marketing Authorisation Application For Cerepro (sitimagene Ceradenovec), Europe

Posted under Cancer by Cancer / Oncology News From Medical News Today

The European Medicines Agency has been formally notified by Ark Therapeutics Ltd of its decision to withdraw its application for a centralised marketing authorisation for the advanced therapy medicinal product Cerepro (sitimagene ceradenovec). Cerepro received an orphan designation on 6 February 2002 and was intended for the treatment of patients with high-grade operable glioma...

[ Read the whole story ]